Replies to post #151299 on Biotech Values

[jq1234]

I don't think you got my point. Both trials were in similar patient population, I agree. But, due to the different mechanism of action, those 40% who didn't get MCyR on ponatinib might be among those 18% who achieved MCyR on Synribo, thus 60% and 18% aren't really overlapping patients. I don't see the two drugs as competitors, by the way.